

Contents

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
1. Fluorescence microscopy methods for the study of protein oligomerization	1
Roberto Arturo Petazzi, Amit Koikkarah Aji, and Salvatore Chiantia	
1. Introduction	2
2. Probing molecular oligomerization: Biophysical and biochemical methods	3
3. Fluorescent tags: Diverse methods to visualize proteins <i>in situ</i>	4
4. Fluorescence-based methods to monitor protein-protein interactions	9
5. Conclusions	28
Acknowledgments	30
References	30
2. Computational prediction and redesign of aberrant protein oligomerization	43
Jaime Santos, Valentín Iglesias, and Salvador Ventura	
1. Introduction	44
2. Molecular determinants behind protein aberrant oligomerization	46
3. Protein aggregation through the prism of evolution: Nature-inspired strategies to ameliorate protein deposition	48
4. From folding to aggregation: Aberrant oligomerization from different native conformations	52
5. Protein deposition in the biotechnological industry: Aggregation out of context	70
6. Conclusions	75
References	75
3. Porphobilinogen synthase: An equilibrium of different assemblies in human health	85
Eileen K. Jaffe	
1. Porphobilinogen synthase—Background	86
2. The structures of PBGS	88
3. The PBGS octamer \rightleftharpoons hexamer equilibrium	91

4. Single amino acid substitutions can dramatically alter the human PBGS quaternary structure equilibrium	95
5. Disease-associated single amino acid variants of human PBGS are hexamer-stabilizing	98
6. Practical and health-related applications of small molecule perturbation of the PBGS quaternary structure equilibrium	99
7. Concluding remarks	101
Acknowledgments	102
References	102
4. Prediction and targeting of GPCR oligomer interfaces	105
Carlos A.V. Barreto, Salete J. Baptista, António José Preto, Pedro Matos-Filipe, Joana Mourão, Rita Melo, and Irina Moreira	
1. Introduction	106
2. Characterization and prediction of oligomer interfaces	109
3. Targeting PPIs: Orthosteric and allosteric modulation	132
4. Concluding remarks	134
Acknowledgments	135
References	136
5. Integrated structural modeling and super-resolution imaging resolve GPCR oligomers	151
Francesca Fanelli, Aylin C. Hanyaloglu, and Kim Jonas	
1. Introduction	152
2. Evidence and pathophysiological role of LHR di/oligomerization	154
3. The FiPD-based approach to model LHR dimerization-oligomerization	163
4. Conclusions	174
Acknowledgments	175
References	175
6. Exploring functional consequences of GPCR oligomerization requires a different lens	181
Kyla Bourque, Jace Jones-Tabah, Dominic Devost, Paul B.S. Clarke, and Terence E. Hébert	
1. Introduction	182
2. Interactions between GPCR protomers require close proximity	183
3. Examples of selected GPCR hetero-oligomers- from in vitro to in vivo	185
4. Allosteric interactions versus canonical receptor crosstalk mediated by protein kinases	187

5. The interaction between the two or more protomers can alter pharmacological properties	190
6. The interaction between the two or more protomers can alter trafficking patterns	193
7. The interaction between the two or more protomers can alter G protein specificity	195
8. The interaction between two or more promoters should be sensitive to mutations or other dimer interfering mechanisms	197
9. An example of allosteric signaling outcomes mediated via FP/AT ₁ R heterodimers	200
10. Concluding remarks	205
References	207

7. Continuing challenges in targeting oligomeric GPCR-based drugs **213**

Joaquin Botta, Julia Appelhans, and Peter J. McCormick

1. Introduction	213
2. Molecular interfaces involved in GPCR oligomerization	218
3. Minimal functional units	221
4. Heteromerization provides new allosteric opportunities	223
5. Heteromer-driven biased signaling	227
6. Heteromers modulate receptor biogenesis, arrestin signaling and trafficking	229
7. Switching of coupling selectivity as a mechanism for signal integration by receptor hetero-oligomers	231
8. Oligomers as drug targets	232
References	236

8. Adenosine A_{2A}-dopamine D₂ receptor-receptor interaction in neurons and astrocytes: Evidence and perspectives **247**

Diego Guidolin, Manuela Marcoli, Cinzia Tortorella, Guido Maura, and Luigi F. Agnati

1. Introduction	248
2. Structural biology of the A _{2A} -D ₂ receptor complex	250
3. Distribution of the A _{2A} -D ₂ receptor complex in cells and tissues	254
4. Pharmacological features of the A _{2A} -D ₂ receptor complex	257
5. A _{2A} -D ₂ heteroreceptor complex: A target for drugs?	261
6. Concluding remarks	265
References	268

9. Genetic variants in dopamine receptors influence on heterodimerization in the context of antipsychotic drug action	279
Agata Faron-Górecka, Maciej Kuśmider, Joanna Solich, Andrzej Górecki, and Marta Dziedzicka-Wasylewska	
1. Introduction	280
2. Effect of SNPs on GPCRs dimerization	283
References	291
Further reading	296
10. Oligomerization of G protein-coupled receptors: Still doubted?	297
Sergi Ferré, Francisco Ciruela, Vicent Casadó, and Leonardo Pardo	
1. Introduction	298
2. Classical GPCR allosterism	299
3. Allosterism in GPCR monomers	300
4. Allosterism in GPCR homomers	303
5. Allosterism in GPCR heteromers	308
6. Molecular architecture of GPCR heteromers	313
7. Final remarks	317
Acknowledgments	317
References	318
Index	323